Dikkat eksikliği ve hiperaktivite bozukluğu olan bir çocukta atomoksetin tedavisi ile kötüleşen kekemelik
Abstract
Kekemelik; her yaşta ortaya çıkabilen, kişinin yaşına ve dil becerilerine uygun olmayan, konuşmanın akıcılığı ve zamanlamasındaki bir bozulma olarak tanımlanmaktadır. Etyolojisinde birçok faktör rol oynamaktadır. İlaçlar da bunlardan biridir. Atomoksetin çocuk ve ergenlerde DEHB tedavisinde sıklıkla tercih edilen ve iyi tolere edilebilen bir ilaçtır. Kekemelik, atomoksetin kullanımı sırasında sık görülen bir yan etki değildir. Bu yazıda 7 yaşında, atomoksetin kullanımı sırasında kekemeliğin belirgin bir şekilde kötüleştiği bir olgu sunulacaktır. Bu olgu için atomoksetin kullanımı sırasında kekemeliğin kötüleştiği çok az sayıda vaka bulunması nedeniyle bildirimde bulunulmuştur.
Keywords
References
- Yairi E, Ambrose N. Epidemiology of stuttering: 21st century advances. J Fluency Disord. 2013;38:66-87.
- Brady ]P. Drug-induced stuttering: a review of the literature. J Clin Psychopharmacol. 1998;18:50-4.
- Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64:205-22.
- Ledbetter M. Atomoxetine: a novel treatment for child and adult ADHD. Neuropsychiatr Dis Treat. 2006;2:455-66.
- Gulle ZN, Karayagmurlu A, Coskun M. Raynaud's phenomenon related with atomoxetine treatment in a child with autism and attention-deficit/hyperactivity disorder. Child Adolesc Psychopharmacol. 2019;29:649-50.
- Karayagmurlu A, Coskun M. Successful management of methylphenidate or atomoxetine-related priapism during attention-deficit hyperactivity disorder treatment. J Clin Psychopharmacol. 2020;40:314-5.
- Guldiken G, Karayagmurlu A. A severe adverse effect of atomoxetine: hypertensive crisis. Clin Neuropharmacol. 2020;43:50-1.
- Cicek AU. Aggravating influence of atomoxetine on the severity of stuttering and its successful treatment with methylphenidate: a case report. Dusunen Adam. 2020;33:210-3.
- Garnock-Jones KP, Keating GM. Atomoxetine. Paediatr Drugs. 2009;11:203-26
Stuttering worsened with atomoxetine treatment in a child with attention deficit and hyperactivity disorder
Abstract
Stuttering; is defined as a deterioration in the fluency and timing of speech that can occur at any age, and which is inappropriate to the individual’s age and language skills. Several factors play a role in its etiology. Medications are one such factor. Atomoxetine is a drug that is frequently employed and well- tolerated in the treatment of attention-deficit hyperactivity disorder in children and adolescents. Stuttering is not a common side- effect when using atomoxetine. This report describes, a seven-year-old patient whose stuttering worsened significantly during atomoxetine use. This case is reported due to the scarcity of cases in which stuttering worsened during the use of atomoxetine.
References
- Yairi E, Ambrose N. Epidemiology of stuttering: 21st century advances. J Fluency Disord. 2013;38:66-87.
- Brady ]P. Drug-induced stuttering: a review of the literature. J Clin Psychopharmacol. 1998;18:50-4.
- Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64:205-22.
- Ledbetter M. Atomoxetine: a novel treatment for child and adult ADHD. Neuropsychiatr Dis Treat. 2006;2:455-66.
- Gulle ZN, Karayagmurlu A, Coskun M. Raynaud's phenomenon related with atomoxetine treatment in a child with autism and attention-deficit/hyperactivity disorder. Child Adolesc Psychopharmacol. 2019;29:649-50.
- Karayagmurlu A, Coskun M. Successful management of methylphenidate or atomoxetine-related priapism during attention-deficit hyperactivity disorder treatment. J Clin Psychopharmacol. 2020;40:314-5.
- Guldiken G, Karayagmurlu A. A severe adverse effect of atomoxetine: hypertensive crisis. Clin Neuropharmacol. 2020;43:50-1.
- Cicek AU. Aggravating influence of atomoxetine on the severity of stuttering and its successful treatment with methylphenidate: a case report. Dusunen Adam. 2020;33:210-3.
- Garnock-Jones KP, Keating GM. Atomoxetine. Paediatr Drugs. 2009;11:203-26
Details
| Primary Language | English |
|---|---|
| Subjects | Child and Adolescent Psychiatry |
| Journal Section | Letter to the Editor |
| Authors | |
| Publication Date | December 29, 2023 |
| Acceptance Date | September 19, 2023 |
| Published in Issue | Year 2023 Volume: 48 Issue: 4 |
